miR-17195 promotes infectious bronchitis virus proliferation and macrophage-mediated inflammation via the PLCβ2-TAK1

Zheng Wang1, Chi Liu2, Xuan Chen1

  • 1Animal Disease Prevention and Green Development Key Laboratory of Sichuan Province, College of Life Science, Sichuan University, Chengdu 610000, China.

Veterinary Microbiology
|December 25, 2025
PubMed

Insights

Infectious Bronchitis virus (IBV) upregulates miR-17195 in chickens, suppressing PLCβ2 to boost viral replication and inflammation. This distinct mechanism drives IBV-induced tissue damage, offering therapeutic targets.

Area of Science:

  • Virology
  • Molecular Biology
  • Immunology

Background:

  • Infectious Bronchitis virus (IBV) causes acute, contagious respiratory and renal disease in poultry.
  • MicroRNAs (miRNAs) are key regulators of host-virus interactions during infection.
  • Understanding viral pathogenesis mechanisms is crucial for disease control.

Purpose of the Study:

  • To investigate the role of host-derived miRNAs in IBV infection.
  • To elucidate the molecular mechanisms by which IBV induces pathogenesis.
  • To identify potential therapeutic targets for mitigating IBV-associated disease.

Main Methods:

  • HD11 cell culture and IBV infection model.
  • Quantitative real-time PCR for miRNA and gene expression analysis.
  • Western blotting to assess protein phosphorylation and signaling pathways.
  • Comparison of PLCβ2 regulation with other avian viruses (NDV, VSV, H9N2).

Main Results:

  • IBV infection upregulates host miR-17195 in HD11 cells.
  • miR-17195 targets and suppresses PLCβ2, enhancing IBV replication.
  • miR-17195 promotes TAK1 phosphorylation, activating JNK/p38/NF-κB signaling and increasing pro-inflammatory cytokines.
  • IBV uniquely uses miR-17195-mediated PLCβ2 downregulation to exacerbate cytokine storm-induced tissue damage.

Conclusions:

  • IBV employs a distinct pathogenesis strategy involving miR-17195-mediated suppression of PLCβ2.
  • This mechanism contributes to IBV-induced multi-organ damage and inflammation.
  • Modulating miR-17195 presents a potential therapeutic avenue for controlling IBV.